UroGen Insider Buying Boosts Optimism Amid Strong Clinical Results
UroGen insider buying signals confidence amid strong ZUSDURI clinical results, sparking optimism for a potential market rally and future commercialization.
3 minutes to read
UroGen Pharma Ltd
UroGen Pharma Insider Sale: CMO Mark Schoenberg’s 6,363‑share RSU Coverage Explained
UroGen Pharma’s CMO Schoenberg Mark sold 6,363 shares for $19.69 each—routine tax‑covering sales that don’t signal a shift, yet insider buying shows confidence amid a volatile, clinical‑stage pipeline.
3 minutes to read